Hikma Eyes Top End Of Forecasts
Generics Sales Will Come Close To $720m In 2019
Hikma has set out updated full-year forecasts in a trading update that indicates its 2019 generics sales will hit the “top end” of its $690m-$720m expectations.
You may also be interested in...
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Helping to alleviate shortages of critical US injectables, including controlled substances, has strengthened Hikma’s relationships with its hospital customers in the US, including with Civica Rx, CEO Siggi Olafsson told Generics Bulletin.
By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.